- Joined
- May 3, 2005
- Messages
- 4,273
- Reaction score
- 2,348
J Opioid Manag. 2009 Mar-Apr;5(2):97-105.
Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients
with chronic pain.
Wallace M, Moulin DE, Rauck RL, Khanna S, Tudor IC, Skowronski R, Thipphawong J.
San Diego Medical Center, University of California, La Jolla, California, USA.
OBJECTIVE: To assess the safety and efficacy of long-term repeated dosing of OROS
hydromorphone in chronic pain patients.
DESIGN: This multicenter, open-label extension trial enrolled patients from three
short-term OROS hydromorphone trials.
SETTING: Fifty-six centers in the United States and Canada.
PATIENTS: Adults with chronic cancer pain or chronic nonmalignant pain who were
receiving stable doses of OROS hydromorphone (> or = 8 mg/day). Three hundred and
eighty-eight patients were enrolled, 106 patients completed at least 12 months of
therapy.
INTERVENTIONS: OROS hydromorphone (individualized doses) was administered once
daily.
MAIN OUTCOME MEASURES: Safety and efficacy (Brief Pain Inventory and patient and
investigator global evaluations) were assessed at monthly visits.
RESULTS: The median duration of extended OROS hydromorphone therapy was 274 days.
The median daily dose of study medication was 32.0 mg at extension-study
baseline, 40.0 mg at month 3, and 48.0 mg at months 6, 9, and 12, respectively.
The most frequently reported adverse events were nausea (n = 93, 24.0 percent)
and constipation (n = 75, 19.3 percent). The analgesic effects of OROS
hydromorphone, assessed using the Brief Pain Inventory, were maintained
throughout the extension. At 12 months, 72.4 percent of patients and 75.9 percent
of investigators rated overall treatment as good, very good, or excellent.
CONCLUSIONS: Once-daily OROS hydromorphone is an osmotically driven,
controlled-release preparation that may be particularly well suited to long-term
use, because it provides consistent plasma concentrations and sustained
around-the-clock analgesia. In this study, the benefits of OROS hydromorphone
attained in short-term studies were maintained in the long-term when daily
administration was continued.
Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients
with chronic pain.
Wallace M, Moulin DE, Rauck RL, Khanna S, Tudor IC, Skowronski R, Thipphawong J.
San Diego Medical Center, University of California, La Jolla, California, USA.
OBJECTIVE: To assess the safety and efficacy of long-term repeated dosing of OROS
hydromorphone in chronic pain patients.
DESIGN: This multicenter, open-label extension trial enrolled patients from three
short-term OROS hydromorphone trials.
SETTING: Fifty-six centers in the United States and Canada.
PATIENTS: Adults with chronic cancer pain or chronic nonmalignant pain who were
receiving stable doses of OROS hydromorphone (> or = 8 mg/day). Three hundred and
eighty-eight patients were enrolled, 106 patients completed at least 12 months of
therapy.
INTERVENTIONS: OROS hydromorphone (individualized doses) was administered once
daily.
MAIN OUTCOME MEASURES: Safety and efficacy (Brief Pain Inventory and patient and
investigator global evaluations) were assessed at monthly visits.
RESULTS: The median duration of extended OROS hydromorphone therapy was 274 days.
The median daily dose of study medication was 32.0 mg at extension-study
baseline, 40.0 mg at month 3, and 48.0 mg at months 6, 9, and 12, respectively.
The most frequently reported adverse events were nausea (n = 93, 24.0 percent)
and constipation (n = 75, 19.3 percent). The analgesic effects of OROS
hydromorphone, assessed using the Brief Pain Inventory, were maintained
throughout the extension. At 12 months, 72.4 percent of patients and 75.9 percent
of investigators rated overall treatment as good, very good, or excellent.
CONCLUSIONS: Once-daily OROS hydromorphone is an osmotically driven,
controlled-release preparation that may be particularly well suited to long-term
use, because it provides consistent plasma concentrations and sustained
around-the-clock analgesia. In this study, the benefits of OROS hydromorphone
attained in short-term studies were maintained in the long-term when daily
administration was continued.